Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Tda1 protein kinase, activated by Snf1 and yeast GSK3-β, fine-tunes metabolism through the phosphorylation of Hxk2, which is ...

difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline ...

difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline clinical data from the randomized Phase 2 study (Actuate-1801 Part 3B ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Hanna will share the results of the study, titled "Elraglusib, a glycogen synthase kinase 3 beta (GSK 3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland ...

Analogues of the natural glucagon-mimetic Glucagon-Like Peptide-1 (GLP-1) reduce body mass and help to prevent type-2 diabetes mellitus and cancer development, partly by inhibiting glycogen synthase ...